Semaglutide 1.0 mg
Sponsors
Novo Nordisk A/S, Fundación para la Investigación del Hospital Clínico de Valencia, Taipei Veterans General Hospital, Taiwan, Yale University, Chinese University of Hong Kong
Conditions
Alcohol Use DisorderBariatric Surgery PatientsCoronary Arterial Disease (CAD)DiabetesDiabetes Mellitus Type 2Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsObesity
Phase 1
A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects
CompletedNCT03288740
Start: 2017-09-21End: 2018-08-07Updated: 2021-02-15
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
Not yet recruitingNCT07223983
Start: 2026-03-01End: 2026-10-31Target: 10Updated: 2026-02-04
Phase 3
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
CompletedNCT03061214
Start: 2017-08-28End: 2019-04-15Updated: 2021-03-02
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
CompletedNCT03552757
Start: 2018-06-04End: 2020-05-01Updated: 2021-11-09
Phase 4
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Active, not recruitingNCT06851962
Start: 2025-05-26End: 2026-06-30Target: 504Updated: 2026-02-23
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms
Not yet recruitingNCT07073053
Start: 2025-10-01End: 2028-07-31Target: 60Updated: 2025-07-18
GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis
Not yet recruitingNCT07251556
Start: 2025-12-01End: 2027-01-01Target: 40Updated: 2025-12-02